1 Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke SW Worm, DA Kamara, P Reiss, E Fontas, S De Wit, W El-Sadr, A D´Arminio Monforte, M Law, A Phillips, L Ryom, NF Dabis, R Weber, C Sabin, JD Lundgren, and on behalf of the D:A:D Study Group
J Infect Dis. 2012 Jan 5. [Epub ahead of print] abstract

2 Projected life expectancy of people with HIV according to timing of diagnosis. F Nakagawa, RK Lodwick, CJ Smith, R Smith, V Cambiano, J Lundgren, V Delpech, AN Phillips.
AIDS. 2012 Jan 28;26(3):335-43. abstract

3 Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes : A cohort study. D Costagliola, R Lodwick, B Ledergerber, C Torti, A van Sighem, D Podzamcer, A Mocroft, et al. The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group.
Lancet Infect Dis. 2012 Jan 28;26(3):315-323. Epub ahead of print 2011 Oct 7. abstract

4 Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. JD Kowalska, J Reekie, A Mocroft, P Reiss, B Ledergerber, J Gatell, AD Monforte, A Phillips, JD Lundgren, O Kirk; for the EuroSIDA study group.
AIDS. 2012 Jan 28;26(3):315-32. Epub 2011 Nov 22. abstract

5 Dampening the effect of drug resistance in HIV: a leap forward. JD Lundgren, JV Lazarus.
Lancet Infect Dis. 2012 Feb;12(2):91-2. abstract

Updated: 06 Feb 2012